Oramed Pharmaceuticals Inc.ORMPNASDAQ
LOADING
|||
Net Income Growth Trend
Above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
264.20%
↑ 1172% above average
Average (39q)
20.78%
Historical baseline
Range
High:513.90%
Low:-312.97%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 264.20% |
| Q2 2025 | 273.88% |
| Q1 2025 | 25.00% |
| Q4 2024 | 48.07% |
| Q3 2024 | -312.97% |
| Q2 2024 | 499.74% |
| Q1 2024 | -88.48% |
| Q4 2023 | 513.90% |
| Q3 2023 | -169.85% |
| Q2 2023 | 33.59% |
| Q1 2023 | 78.95% |
| Q4 2022 | -17.79% |
| Q3 2022 | 31.14% |
| Q2 2022 | -1.04% |
| Q1 2022 | -32.13% |
| Q4 2021 | -15.13% |
| Q3 2021 | -31.61% |
| Q2 2021 | -13.00% |
| Q1 2021 | 17.27% |
| Q4 2020 | -85.91% |
| Q3 2020 | -31.17% |
| Q2 2020 | 38.07% |
| Q1 2020 | -45.03% |
| Q4 2019 | -11.54% |
| Q3 2019 | 44.01% |
| Q2 2019 | -10.02% |
| Q1 2019 | 13.97% |
| Q4 2018 | -47.03% |
| Q3 2018 | 32.80% |
| Q2 2018 | -49.31% |
| Q1 2018 | -15.21% |
| Q4 2017 | 6.12% |
| Q3 2017 | -37.20% |
| Q2 2017 | 38.27% |
| Q1 2017 | -20.75% |
| Q4 2016 | 44.62% |
| Q3 2016 | -138.48% |
| Q2 2016 | -9.79% |
| Q1 2016 | 23.93% |
| Q4 2015 | -12.95% |